The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
Guerry Cook(Wake Forest University), Timothy S. Pardee(Atrium Health Wake Forest Baptist)
Cited by 8
Related Papers
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity
|Cell Metabolism|2019|112
The Glutamine-Rich Activation Domains of Human Sp1 Do Not Stimulate Transcription in <i>Saccharomyces cerevisiae</i>
|Molecular and Cellular Biology|1995|54
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia
|Nature Cancer|2022|42